Page 6 - Mankind Pharma

Mankind Pharma's Rs 4,326-crore IPO: Issue subscribed 14% on Day 1

The company's IPO closed on Thursday

Mankind Pharma IPO subscribed 8% so far on Day 1; GMP down 30% in 10 days

The Rs 4,326-crore public issue's price band is set in the range of Rs 1,026-1,080 per share. The issue will close on Thursday, April 27

Mankind Pharma IPO opens today: Check GMP, price band, other details here

Mankind Pharma IPO listing date: The IPO is likely to list on NSE and BSE on May 8

Mankind Pharma raises Rs 1,298 cr from anchor investors ahead of IPO

Canada Pension Plan Investment Board (CPPIB), the Government of Singapore, SBI Multi Cap Fund, and Fidelity Investment Trust were some investors who were allotted shares under the anchor quota

Is Mankind Pharma IPO worth a subscription? Here's what brokerages suggest

In the grey markets, shares of Mankind Pharma enjoyed a premium of Rs 90, which translated to a likely listing price of Rs 1,170 per share on the upper price band

Street signs: Defence stocks may rise, Mankind Pharma IPO, and more

After having recorded seven straight months of outflows, equity savings schemes are expected to witness a change of fortune in the months ahead

Mankind Pharma's Rs 4,326-crore initial public offering to open April 25

The offering is entirely a secondary share sale by promoters, global private equity firm Cairnhill and some other investors of the firm

Mankind Pharma IPO to open next week: Check price band, GMP, other details

Mankind Pharma IPO GMP: According to reports, the IPO is commanding a great market premium of Rs 80 per share today

Top Headlines: Mankind's quality assurance, India in space economy and more

Business Standard brings you the top headlines at this hour

Stocks to Watch: HCL Tech, Lupin, Fusion Micro Fin, Five-Star, NBCC, PNB

Stocks to Watch Today: Newly listed Fusion Micro Finance and Five-Star Business are likely to be in focus on the back of strong Q2 performance reported by the companies.

Mankind Pharma acquires stake in Upakarma Ayurveda for undisclosed sum

Mankind Pharma on Monday said it has acquired a majority stake in Upakarma Ayurveda, engaged in developing, manufacturing and selling ayurvedic and herbal products for an undisclosed amount. The company's decision to invest will empower Upakarma Ayurveda to develop a wider range of products and offerings, the drug firm said in a statement. "The current lifestyle has become strenuous where people find it difficult to focus on their health. To fulfil their requirements, consumers are considering Ayurvedic remedies for long-term sustenance and boosting immunity over time. "As Mankind Pharma works towards improving the healthcare of people, we have associated with Upakarma Ayurveda in order to cater to the emerging needs of consumers," Mankind Pharma Vice Chairman and Managing Director Rajeev Juneja said. Mankind Pharma acquired the ayurvedic soulutions firm through one of its subsidiaries. Upakarma Ayurveda Founder & Managing Director Vishal Kaushik said that with the partnership, ..

Expensive deal valuations to hit Torrent Pharma's near-term earnings

Sales trajectory in domestic formulations and resolution of regulatory issues are other triggers

Mankind Pharma files for IPO, could be second largest among pharma firms

The offer for sale is expected to be anywhere between Rs 5000-5500 crore, say sources

Mankind Pharma forays into agri-tech space, plans to invest Rs 200 crore

Mankind Pharma on Monday announced its foray into the agri-tech segment, with plans to invest up to Rs 200 crore in the first two to three years

From Coca-Cola to Apple Inc, here are India's best unlisted companies

In all, 18 out of the best 30 unlisted companies in the 2021 league table are local subsidiaries of global multinationals.

Stocks to Watch: DRL, Mankind, Sun Pharma, Wipro, Kalpataru, TTML, Airlines

Ambuja Cement, Nestle India and Veritas to announce December quarter results today.

Mankind Pharma acquires two derma and respiratory brands from Dr Reddy's

Mankind Pharma to take over manufacturing, marketing and distribution of both products in India; entire integration and transition of the brands likely to be completed by March

Mankind Pharma signs agreement to buy Panacea Biotec Pharma's domestic biz

Panacea Biotec Pharma is a subsidiary of vaccine maker Panacea Biotec; its domestic biz had a turnover of Rs 219 cr in FY21; Adar Poonawalla holds 8.6% stake in the firm

Covid-19 & low base in 2020 boost anti-infectives growth, shows data

Antibiotics, antivirals spur drug category; chronic therapies post lower numbers

Mankind, BDR Pharma join hands to launch anti Covid-19 pill Molulife

Mankind Pharma on Wednesday said it has joined hands with BDR Pharmaceuticals to launch oral anti COVID-19 pill Molulife (Molnupiravir) in the country. The tie-up is a licensing arrangement where production is by BDR Pharma and marketing, selling, promotion, distribution is by Mankind Pharma, the company said in a statement. On Tuesday, the Drugs Controller General of India (DCGI) granted permission for restricted use of antiviral medication Molnupiravir under emergency situation for treatment of COVID-19 in adult patients who have a high risk of progression of the disease. This launch further enhances the COVID-19 treatment portfolio in BDR's product basket with the addition of generic Molnupiravir. We are pleased to collaborate with Mankind Pharma to take one step forward in fighting the virus," BDR Pharma Director Business Development Raheel Shah stated. Mankind Pharma Senior President (Sales & Marketing) Sanjay Koul noted that a pill for COVID-19 is bound to go miles in ...